Save time and get answers to complex questions with AI chat
Adefovir dipivoxil discount cardIs liver function monitoring necessary with lipitorEnhertu loss of exclusivity patent expirationOzempic jordan price 2026Nicardipine brand names
See the DrugPatentWatch profile for pembrolizumab
Pembrolizumab targets and inhibits the PD-1 receptor on T cells (CD279). It binds PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2, lifting the inhibitory PD-1 pathway to re-activate T-cell anti-tumor activity.
Other Questions About Pembrolizumab :